Teva spent $5.6 million on lobbying in 2017 and has spent $37 million over the past 10 years.
Valeant charges $21,267 for 100 branded Syprine tablets. Bernie Sanders: Do we have the guts to stand up to drug companies who are ripping us off?
ALYNnovation takes medical innovations developed at the ALYN pediatric rehabilitation hospital out of the hospital so that all children can benefit from them.
Leader Capital Market: There is great uncertainty about Teva's future growth potential.
The German pharmaceutical company is cooperating with Arkin Bio Ventures, Pontifax Fund, and WuXi Apptec.
The Israeli company adapts its reminders to the patient's age and the type of medicine.
OrCam, which has developed a wearable aid for people with impaired vision, raised $30.4 million in a round led by Clal Insurance and Meitav Dash Provident Funds and Pension Ltd.
Tirat Hacarmel based Motus GI has developed Pure-Vu for cleaning the colon in advance of a colonoscopy.
Stream Net is a thrombectomy device designed to address unmet clinical needs in the treatment of acute ischemic stroke.
Freddy Zinger does not rule out buying Teva Migada in Kiryat Shmona, the company he founded.
Kare Schultz has stabilized the ship but faces enormous opposition to his streamlining plan.
Every change in Teva's business is amplified in its share price.
Teva, Israel's universities and the state should join forces to find and develop new drugs, says Prof. Eyal Winter.
Teva's contribution to Israel's tax revenues has been virtually zero.
As Teva workers await the axe, one tells "Globes" that he fears he will be shortchanged while outgoing CSO Michael Hayden gets $2.5 million by the end of 2018.
Former Teva chairman Meir Heth believes the company's top executives are responsible for the current situation.
Some financial institutions see an opportunity in Teva's low share price and have increased their holdings in the company.
Princeton University's Prof. Dalton Conley tells "Globes" that understanding the interaction between genetics and environment will start a social revolution.
Analyst Steven Tepper tells "Globes" that if Teva wants to stay independent, it needs capital, or it will be exposed to a takeover.
Prof. Gideon Gross is suing Prof. Zelig Eshhar, alleging that Eshhar cheated him out of his share of the $11.9 billion sale of Kite, which has developed a revolutionary cancer drug.
More energetic than ever, Arie Belldegrun talks to "Globes" about Kite Pharma's remarkable journey and the future of cancer treatment.
Accelmed seeks to replicate its success formula in urology, as portfolio company Cogentix makes a third acquisition.
Israeli company Essence develops products that enable people to keep living at home in old age.
The Weizmann Institute researcher's groundbreaking research on Alzheimer's Disease is leading to new treatment for it.